Article
Oncology
Yihua Huang, Chunwei Xu, Yuanliang Sun, Wenxian Wang, Xingya Li, Jun Liao, Lanlan Pang, Liang Zeng, Juan Li, Xihua Wang, Qi Zhang, Zhanhong Xie, Lin Xiao, Jiadi Gan, Wenfeng Fang
Summary: This study investigated the molecular distribution and clinical outcomes of Chinese patients with EGFR E709-T710delinsX mutations. The results showed that afatinib may have superior antitumor activity compared to 1G EGFR TKIs and chemotherapy in EGFR E709-T710delinsX mutant patients.
Article
Oncology
Lingzhi Hong, Whitney E. Lewis, Monique Nilsson, Sonia Patel, Susan Varghese, Melvin J. Rivera, Robyn R. Du, Pingjun Chen, Haley N. Kemp, Waree Rinsurongkawong, Simon Heeke, Amy R. Spelman, Yasir Y. Elamin, Marcelo Negrao, Boris Sepesi, Don L. Gibbons, J. Jack Lee, Jia Wu, Natalie Vokes, John Heymach, Jianjun Zhang, Xiuning Le
Summary: The addition of anti-PD1 immunotherapy did not provide additional benefit to chemotherapy for EGFR-mutant LUAD patients with TKI resistance. However, there was a trend towards benefit with anti-VEGF therapy. The ideal choice for post-TKI treatment is still being evaluated.
Review
Oncology
Yvette N. Lamb
Summary: Osimertinib is an effective treatment for non-small cell lung cancer, prolonging survival and showing good tolerability in patients.
Article
Pharmacology & Pharmacy
Ying Xie, Sen-ling Feng, Fang He, Pei-Yu Yan, Xiao-Jun Yao, Xing-Xing Fan, Elaine Lai-Han Leung, Hua Zhou
Summary: This study investigates the potential of targeting the Nrf2 pathway to overcome acquired drug resistance and enhance the therapeutic effects of chemotherapy and molecular-targeted therapy. It demonstrates that upregulation of Nrf2 in Gefitinib-resistant and paclitaxel-resistant lung cancer cells is an important mechanism.
PHARMACOLOGICAL RESEARCH
(2022)
Article
Oncology
Gad Rennert, Maya Gottfried, Hedy S. Rennert, Flavio Lejbkowicz, Meira Frank, Ilana Cohen, Shiri Kelt, Abed Agbarya, Elizabeta Dudnik, Julia Dudnik, Rivka Katznelson, Moshe Mishali, Natalie Maimon Rabinovich, Hovav Nechushtan, Amir Onn, Shoshana Keren Rosenberg, Mariana Wollner, Alona Zer, Jair Bar, Naomi Gronich
Summary: The study showed that TKIs provided to EGFR mutated advanced NSCLC patients resulted in significant survival benefits for at least five years, but treating non-EGFR mutated NSCLC patients with TKIs seemed detrimental. Squamous histology, smoking, male sex, and Arab ethnicity were associated with higher NSCLC mortality hazard.
TRANSLATIONAL ONCOLOGY
(2021)
Article
Oncology
Jon Apple, Rahul Shenolikar, Kevin De Silva, Ping Sun, Alexander Spira
Summary: This study evaluated the initiation of first-line therapy in EGFRm mNSCLC patients based on biomarker testing results. The results showed that EGFR TKIs as first-line therapy had better treatment outcomes compared to IO and chemotherapy.
Review
Pharmacology & Pharmacy
Paul Zarogoulidis, Christoforos Kosmidis, Isaak Kesisoglou, Kosmas Tsakiridis, Wolfgang Hohenforst-Schmidt, Haidong Huang, Konstantinos Romanidis, Anastasios Vagionas, Konstantinos Sapalidis
Summary: Nutrition plays a crucial role in the treatment of non-small cell lung cancer patients. Food supplements can assist in improving quality of life. Prevention is still considered the best approach to deal with this disease, with patients receiving different treatments depending on individual circumstances.
CURRENT PHARMACEUTICAL DESIGN
(2021)
Article
Multidisciplinary Sciences
Qian Jin, Feihua Huang, Xianrong Xu, Haidong He, Yingqing Zhang
Summary: The study found that the expression of HIF-1 alpha in EGFR-TKIs sensitive NSCLC tissue was significantly higher, and the level of HIF-1 alpha increased further after acquiring resistance. There was a negative correlation between HIF-1 alpha level and the occurrence time of acquired resistance as well as the acquired EGFR T790M mutation.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Yasir Y. Elamin, Jacqulyne P. Robichaux, Brett W. Carter, Mehmet Altan, Hai Tran, Don L. Gibbons, Simon Heeke, Frank Fossella, Vincent K. Lam, Xiuning Le, Marcelo Negrao, Monique B. Nilsson, Anisha Patel, R. S. K. Vijayan, Jason B. Cross, Jianjun Zhang, Lauren A. Byers, Charles Lu, Tina Cascone, Lei Feng, Rajyalakshmi Luthra, Francis A. San Lucas, Geeta Mantha, Mark Routbort, George Blumenschein, Anne S. Tsao, John Heymach
Summary: This study reports the efficacy of poziotinib in treating NSCLC patients with EGFR exon 20 mutations and highlights the importance of insertion location in determining drug sensitivity. The study found that near-loop insertions were more sensitive to poziotinib than far-loop insertions. Furthermore, potential mechanisms of acquired resistance were identified.
Article
Oncology
Weiguang Gu, Hua Zhang, Yiyu Lu, Minjing Li, Shuang Yang, Jianmiao Liang, Zhijian Ye, Zhihua Li, Minhong He, Xiaoliang Shi, Fei Wang, Dong You, Weiquan Gu, Weineng Feng
Summary: In this multicenter clinical trial in China, we investigated the efficacy of adding pemetrexed to improve progression-free survival (PFS) in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients. There were no significant differences in PFS between patients with or without concomitant alterations, or between patients receiving EGFR-tyrosine kinase inhibitor (TKI) monotherapy or combined with pemetrexed. However, stratification analysis revealed that TKI monotherapy showed better PFS in non-concomitant group, while TKI combined with pemetrexed showed better PFS in concomitant group. Molecular dynamic analysis supported the better efficacy of TKI combined chemotherapy compared to TKI monotherapy. Additionally, circulating tumor DNA (ctDNA) minimal residual disease (MRD) showed potential as a biomarker for predicting therapeutic efficacy.
CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Li Sun, Yi-Jia Guo, Jun Song, Yan-Ru Wang, Shu-Ling Zhang, Le-Tian Huang, Jian-Zhu Zhao, Wei Jing, Cheng-Bo Han, Jie-Tao Ma
Summary: The neoadjuvant EGFR-TKI therapy shows feasibility in treating patients with resectable or potentially resectable EGFR-mutant NSCLC, with satisfactory surgical outcomes and low toxicity. Further phase III clinical trials are needed to confirm these findings and explore the feasibility of a more effective EGFR-TKI combination neoadjuvant therapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Andres F. Cardona, Camila Ordonez-Reyes, Alejandro Ruiz-Patino, Juan Esteban Garcia-Robledo, Lucia Zatarain Barron, Gonzalo Recondo, Leonardo Rojas, Luis Corrales, Claudio Martin, Feliciano Barron, Carolina Sotelo, July Rodriguez, Luisa Ricaurte, Christian Rolfo, Jenny Avila, Diana Mayorga, Pilar Archila, Jorge Otero, Luis Mas, Maritza Bermudez, Tatiana Gamez, Hernan Carranza, Carlos Vargas, Rafael Rosell, Oscar Arrieta
Summary: The addition of bevacizumab to EGFR-TKIs resulted in a significantly higher overall response rate and longer progression-free survival in advanced NSCLC patients with EGFR mutation and BIM deletion. Further prospective studies are needed to confirm these findings.
JCO PRECISION ONCOLOGY
(2021)
Article
Oncology
Giorgia Nardo, Jessica Carlet, Ludovica Marra, Laura Bonanno, Alice Boscolo, Alessandro Dal Maso, Andrea Boscolo Bragadin, Stefano Indraccolo, Elisabetta Zulato
Summary: The study found that co-existing KRAS mutations in EGFR mutated NSCLC patients at progression after first-line EGFR TKI treatment are rare, and they have a negative impact on the response to EGFR TKI.
FRONTIERS IN ONCOLOGY
(2021)
Review
Pharmacology & Pharmacy
Yazan Haddad, Marek Remes, Vojtech Adam, Zbynek Heger
Summary: The study utilized variations in 110 crystal structures to assemble eight distinct families highlighting the C-helix orientation in the N-lobe of the EGFR kinase domain. These families shared similar mutational profiles, ligand R-groups facing the C-helix, mutation sites, and DFG domain.
DRUG DISCOVERY TODAY
(2021)
Article
Medicine, Research & Experimental
Hui Hua, Jiajia Zeng, Haixin Xing, Yuxin He, Linyu Han, Nasha Zhang, Ming Yang
Summary: This study systematically evaluated the role of genetic variants in A-to-I editing genes on the prognosis of NSCLC patients receiving EGFR-TKIs therapy. The researchers identified several SNPs in the ADAR gene that were significantly associated with patient prognosis and found that silencing ADAR enhanced the sensitivity of NSCLC cells to gefitinib. These findings highlight the importance of A-to-I RNA editing in drug resistance and suggest ADAR as a potential therapeutic target for unresectable NSCLC.
Article
Oncology
E. Gobbini, R. Chiari, P. Pizzutillo, P. Bordi, L. Ghilardi, S. Pilotto, G. Osman, F. Cappuzzo, F. Cecere, F. Riccardi, V Scotti, O. Martelli, G. Borra, E. Maiello, A. Rossi, P. Graziano, V Gregorc, C. Casartelli, C. Sergi, A. Del Conte, A. Delmonte, C. Bareggi, D. Cortinovis, P. Rizzo, F. Tabbo, G. Rossi, E. Bria, D. Galetta, M. Tiseo, M. Di Maio, S. Novello
CLINICAL & TRANSLATIONAL ONCOLOGY
(2020)
Article
Oncology
Aldo Pezzuto, Federico Cappuzzo, Manolo D'Arcangelo, Massimo Ciccozzi, Luca Navarini, Simone Guerrini, Alberto Ricci, Michela D'Ascanio, Elisabetta Carico
ANTICANCER RESEARCH
(2020)
Article
Oncology
Angelo Castello, Sabrina Rossi, Luca Toschi, Luigi Mansi, Egesta Lopci
Article
Oncology
Alessio Cortellini, Alex Friedlaender, Giuseppe L. Banna, Giampiero Porzio, Melissa Bersanelli, Federico Cappuzzo, Joachim G. J. Aerts, Raffaele Giusti, Emilio Bria, Diego Cortinovis, Francesco Grossi, Maria R. Migliorino, Domenico Galetta, Francesco Passiglia, Rossana Berardi, Francesca Mazzoni, Vincenzo Di Noia, Diego Signorelli, Alessandro Tuzi, Alain Gelibter, Paolo Marchetti, Marianna Macerelli, Francesca Rastelli, Rita Chiari, Danilo Rocco, Alessandro Inno, Pietro Di Marino, Giovanni Mansueto, Federica Zoratto, Matteo Santoni, Marianna Tudini, Michele Ghidini, Marco Filetti, Annamaria Catino, Pamela Pizzutilo, Luca Sala, Mario Alberto Occhipinti, Fabrizio Citarella, Russano Marco, Mariangela Torniai, Luca Cantini, Alessandro Follador, Vincenzo Sforza, Olga Nigro, Miriam G. Ferrara, Ettore D'Argento, Alessandro Leonetti, Linda Pettoruti, Lorenzo Antonuzzo, Simona Scodes, Lorenza Landi, Giorgia Guaitoli, Cinzia Baldessari, Federica Bertolini, Luigi Della Gravara, Maria Giovanna Dal Bello, Robert A. Belderbos, Marco De Filippis, Cristina Cecchi, Serena Ricciardi, Clelia Donisi, Alessandro De Toma, Claudia Proto, Alfredo Addeo, Ornella Cantale, Biagio Ricciuti, Carlo Genova, Alessandro Morabito, Daniele Santini, Corrado Ficorella, Katia Cannita
CLINICAL LUNG CANCER
(2020)
Letter
Oncology
Diego Cortinovis, Maria Gemelli, Federico Cappuzzo
JOURNAL OF THORACIC ONCOLOGY
(2020)
Review
Oncology
Daniele Marinelli, Raffaele Giusti, Marco Mazzotta, Marco Filetti, Eriseld Krasniqi, Laura Pizzuti, Lorenza Landi, Silverio Tomao, Federico Cappuzzo, Gennaro Ciliberto, Maddalena Barba, Patrizia Vici, Paolo Marchetti
Summary: Glucocorticoids play a crucial role in managing immune-related adverse events and symptoms in cancer patients. The purpose of glucocorticoid administration may impact the survival outcomes of cancer patients undergoing immune-checkpoint inhibitor treatment.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Letter
Oncology
Raul Pellini, Flaminia Campo, Domenico Sergi, Federico Cappuzzo
Article
Oncology
Maddalena Barba, Eriseld Krasniqi, Laura Pizzuti, Marco Mazzotta, Daniele Marinelli, Greta Giuliano, Francesca Sofia Di Liso, Federico Cappuzzo, Lorenza Landi, Silverio Tomao, Gennaro Ciliberto, Patrizia Vici
Summary: The COVID-19 pandemic has led to significant changes in the management of cancer patients worldwide, including reduced screening, delayed surgeries and radiotherapy, as well as dose reductions or delays in systemic therapy administration, such as CDK 4/6 inhibitors.
Article
Oncology
Vanesa Gregorc, Luca Mazzarella, Chiara Lazzari, Paolo Graziano, Paolo Vigneri, Carlo Genova, Luca Toschi, Gennaro Ciliberto, Laura Bonanno, Angelo Delmonte, Gabriele Bucci, Antonio Rossi, Gianmarco Motta, Simona Coco, Arianna Marinello, Simonetta Buglioni, Maria Giulia Cangi, Concetta Di Micco, Alessandro Bandiera, Silvia Bonfiglio, Lorenza Pecciarini, Alessandro Guida, Arnaud Ceol, Gianmaria Frige, Ruggero De Maria, Pier Giuseppe Pelicci
Summary: In Italy, heterogeneity in molecular assessment of non-small-cell lung cancer (NSCLC) has prompted the Alliance Against Cancer (ACC) to develop a targeted sequencing panel for NSCLC patients, with 1000 metastatic NSCLC patients enrolled in a prospective trial. This trial is part of a nationwide strategy to increase the number of patients with a molecular classification and enhance the genomic profiling capabilities of Italian research institutes.
CLINICAL LUNG CANCER
(2021)
Article
Medicine, General & Internal
Angelo Castello, Sabrina Rossi, Luca Toschi, Egesta Lopci
Summary: The study found that the use of antibiotics is associated with poorer treatment response, PFS, and higher metabolic tumor burden in NSCLC patients treated with immune checkpoint inhibitors.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Medicine, General & Internal
Eriseld Krasniqi, Maddalena Barba, Aldo Venuti, Laura Pizzuti, Federico Cappuzzo, Lorenza Landi, Silvia Carpano, Paolo Marchetti, Alice Villa, Enrico Vizza, Greta Giuliano, Marco Mazzotta, Daniele Marinelli, Sandra Gnignera, Cristina Vincenzoni, Vincenzo Stranges, Domenico Sergi, Antonio Giordano, Federica Tomao, Marcello Maugeri-Sacca, Giuseppe Sanguineti, Francesca Sofia Di Lisa, Silverio Tomao, Gennaro Ciliberto, Patrizia Vici
Summary: HPVs are linked to cervical and oropharyngeal cancers, and circulating HPV DNA serves as a potential biomarker for clinical management. Specific and minimally invasive tests can enable early detection and treatment monitoring, with innovative techniques enhancing the detection rate of serum HPV DNA.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Sabrina Rossi, Paola Damiano, Luca Toschi, Giovanna Finocchiaro, Laura Giordano, Arianna Marinello, Emilio Bria, Ettore D'Argento, Armando Santoro
Summary: Molecular characterization of non-small-cell lung cancer is crucial for determining the appropriate treatment plan. This study found that patients with compound EGFR mutations had longer overall survival and potentially better response to targeted therapies. Chemotherapy was effective for specific mutations, and the addition of immunotherapy could impact future treatment strategies.
CURRENT PROBLEMS IN CANCER
(2022)
Meeting Abstract
Oncology
Robin Meng, Benjamin Besse, Melissa Johnson, Jaafar Bennouna, Luca Toschi, Giovanni Abbadessa, Amele Amrate, Miao Zang, Luis Paz Ares
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Meeting Abstract
Oncology
B. Melosky, E. Laack, K. Kambartel, M. Haentschel, M. Bennetts, D. Nickens, J. Brinkmann, A. Kayser, M. Moran, F. Cappuzzo
JOURNAL OF THORACIC ONCOLOGY
(2021)
Meeting Abstract
Oncology
D. R. Spigel, D. Rodriguez-Abreu, F. Cappuzzo, V. Velcheti, A. K. Ganti, D. Johnson, R. Govindan, S. Antonia, B. Besse, M. Altan, M. Edelman, S. Ramalingam, E. Felip, S. Gadgeel, O. Juan-Vidal, A. Gupta, S. Currie, W. Lin, M. Tagliaferri, M. Reck
JOURNAL OF THORACIC ONCOLOGY
(2021)